Top Ten FDA-Approved Biosimilars Ranked by Therapeutic Importance and Value

Biosimilars are biologic medical products that are highly similar to already approved reference biologics, with no clinically meaningful differences in safety, purity, or potency. They play a critical role in healthcare by increasing access to expensive biologic treatments, driving down costs, and fostering competition in the pharmaceutical market. Below is a ranked list of the top ten biosimilars recently approved by the FDA, based on their therapeutic importance and market value.

Ranked List of Biosimilars

Highlights of Key Approvals

1. Merilog: Approved in February 2025, Merilog is the first biosimilar to NovoLog for diabetes treatment. It addresses a critical need for affordable insulin options.
2. Ospomyv: Approved in February 2025, this biosimilar to Prolia offers an alternative for osteoporosis patients at high risk of fractures.
3. Tyruko: The first natalizumab biosimilar approved for relapsing forms of multiple sclerosis in August 2023.
4. Selarsdi: Approved in April 2024, Selarsdi targets autoimmune conditions like Crohn's disease and psoriasis.
5. Jubbonti: An interchangeable biosimilar to Prolia approved in March 2024 for various osteoporosis-related indications

Citations:

1. https://www.gabionline.net/biosimilars/general/biosimilars-approved-in-the-us
2. https://www.bigmoleculewatch.com/fda-approved-ablas/
3. https://www.drugs.com/history/merilog.html
4. https://www.drugs.com/history/ospomyv.html
5. https://www.drugs.com/history/jubbonti.html
6. https://www.centerforbiosimilars.com/view/fda-approves-amgens-infliximab-biosimilar-avsola
7. https://www.centerforbiosimilars.com/view/alvotech-s-stelara-biosimilar-selarsdi-receives-fda-approval
8. https://www.managedhealthcareexecutive.com/view/wezlana-first-stelara-biosimilar-to-hit-the-market-available-only-through-optum-private-label
9. https://www.novartis.com/news/media-releases/sandoz-receives-fda-approval-tyruko-natalizumab-sztn-first-and-only-fda-approved-biosimilar-relapsing-forms-multiple-sclerosis
10. https://www.drugs.com/medical-answers/many-biosimilars-approved-united-states-3463281/
11. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-and-Alvotech-Announce-SELARSDI-ustekinumab-aekn-Injection-Now-Available-in-the-U.S/default.aspx
12. https://invimeds.com/news/fda-approves-wezlana-as-an-interchangeable-biosimilar-to-stelara-for-multiple-inflammatory-diseases/
13. https://www.drugs.com/history/tyruko.html
14. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Alvotech-and-Teva-Announce-U.S.-FDA-Approval-of-SELARSDI-ustekinumab-aekn-biosimilar-to-Stelara-ustekinumab/default.aspx
15. https://www.centerforbiosimilars.com/view/fda-approves-first-stelara-biosimilar-wezlana
16. https://www.centerforbiosimilars.com/view/a-banner-year-for-biosimilars-the-18-fda-approvals-from-2024
17. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
18. https://www.managedhealthcareexecutive.com/view/the-biosimilars-report-card
19. https://www.centerforbiosimilars.com/view/from-amjevita-to-zarxio-a-decade-of-us-biosimilar-approvals
20. https://www.centerforbiosimilars.com/approvals-launches
21. https://www.techtarget.com/pharmalifesciences/feature/Exploring-FDA-approved-biosimilar-insulin-products
22. https://www.segalco.com/consulting-insights/q1-2025-trends-focus-biosimilars
23. https://www.ajmc.com/view/first-insulin-aspart-biosimilar-receives-fda-approval
24. https://www.bigmoleculewatch.com/2025/02/17/regulatory-updates-on-samsungs-denosumab-biosimilars/
25. https://uk.marketscreener.com/quote/stock/SANDOZ-GROUP-AG-160016887/news/Sandoz-FDA-approves-Wyost-and-Jubbonti-46100565/
26. https://www.goodwinlaw.com/en/insights/blogs/2019/12/fda-approves-amgens-avsola-infliximabaxxq
27. https://www.centerforbiosimilars.com/view/fda-approves-pfizers-second-biosimilar-infliximab-ixifi
28. https://www.biospace.com/samsung-bioepis-announces-first-real-world-data-on-renflexis-infliximab-abda-with-ibd-patients-from-veterans-affairs-healthcare-system-at-the-american-college-of-gastroenterology-acg-2020
29. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_the_u_s_availability_of_biosimilar_inflectra_infliximab_dyyb
30. https://www.centerforbiosimilars.com/view/fda-approves-first-insulin-aspart-biosimilar
31. https://www.centerforbiosimilars.com/view/fda-approves-first-ms-biosimilar
32. https://www.selarsdi.com
33. https://www.centerforbiosimilars.com/view/welcome-wezlana-the-first-stelara-biosimilar-to-launch-in-the-us
34. https://www.drugs.com/history/ixifi.html
35. https://www.merck.com/news/merck-announces-u-s-launch-of-renflexis-infliximab-abda-a-biosimilar-of-remicade-for-all-eligible-indications/
36. https://biosimilarsrr.com/product-profile-inflectra-2/

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!